![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
August 16, 2022
This phase 3 study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
January 25, 2021
This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma